- Home
- / Kymera Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Kymera Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$48.5
2024-10-29
Market Capitalization
$3.1 B
2024-10-29
Revenue
$39.2 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 34.0M | 72.8M | 46.8M | 78.6M | 47.1M | 39.2M |
| Cost of goods sold | 47.1M | 39.2M | ||||
| General and administrative expense | 18.2M | 36.3M | 43.8M | 55.0M | 63.5M | 68.2M |
| Operating expense total | 80.3M | 173.4M | 208.1M | 244.1M | 261.6M | 349.4M |
| EBIT | (46.3M) | (100.5M) | (161.3M) | (165.5M) | (261.6M) | (349.4M) |
| EBIT margin, % | -136.1% | -138.0% | -344.4% | -210.6% | -555.8% | -891.1% |
| Interest income | 38.0M | 38.4M | ||||
| Interest expense | 115.0K | 158.0K | 179.0K | 162.0K | 206.0K | |
| Pre tax profit | (311.4M) | |||||
| Net Income | (45.6M) | (100.2M) | (154.8M) | (147.0M) | (223.9M) | (311.4M) |
| EPS | (2.9) | (2.5) | (3.0) | (3.7) |